Update: Morgan Stanley Lifts Price Target on Alibaba to $190 From $180, Maintains Overweight Rating

(Updates with Morgan Stanley's commentary.)

Morgan Stanley raised its price target on Alibaba (BABA) to $190 From $180 while keeping its overweight rating.

The brokerage said Alibaba subsidiary Alicloud "delivered on all key matrices" it tests and the tech firm showed "rapid AI [artificial intelligence] product revenue growth."

External Alicloud revenue increased 44% in fiscal Q1 2027 and Alibaba expects the unit's margin to increase to 11% in fiscal Q1 2027, Morgan Stanley said in its note.

Alibaba has an average rating of buy and mean price target of $191.17, according to analysts polled by FactSet.

(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)

Price: $142.96, Change: $-2.85, Percent Change: -1.95%

Argus Lowers McDonald's Price Target to $320 From $380

McDonald's (MCD) has an average rating of overweight and mean price target of $332.47, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $275.01, Change: $-0.69, Percent Change: -0.25%

$MCD

Update: Regenxbio Shares Fall After Q1 Swings to Loss, Revenue Declines; Phase 3 Study of RGX-202 Meets Primary Endpoint

(Updates with latest stock price movement in the headline and first paragraph, Q1 earnings in the second through sixth paragraphs.)Regenxbio's (RGNX) shares were down about 36% in Thursday afternoon trading after its Q1 swung to a loss and revenue declined.The company reported a Q1 net loss Thursday of $1.72 per diluted share, swinging from earnings of $0.12 a year earlier.Analysts polled by FactSet expected a loss of $1.34.Revenue for the quarter ended March 31 fell to $6.4 million from $89.0 million a year earlier.Analysts surveyed by FactSet expected $25.8 million.The company expects its cash, cash equivalents and marketable securities of $150.5 million as of March 31 to fund its operations into early 2027.Separately, the company said Thursday its investigational gene therapy RGX-202 met the primary endpoint in the pivotal phase III portion of the Affinity Duchenne trial for Duchenne Muscular Dystrophy.The company said 93% of patients achieved over 10% microdystrophin expression at week 12.Regenxbio said it is preparing to pursue accelerated approval based on the data and is targeting a potential commercial launch in 2027.Price: $6.47, Change: $-3.57, Percent Change: -35.56%

$RGNX

Update: Morgan Stanley Lifts Price Target on Alibaba to $190 From $180, Maintains Overweight Rating

Related Articles

Argus Lowers McDonald's Price Target to $320 From $380

Update: Regenxbio Shares Fall After Q1 Swings to Loss, Revenue Declines; Phase 3 Study of RGX-202 Meets Primary Endpoint

Altria Maintains Quarterly Dividend at $1.06 per Share, Payable July 10 to Holders of Record June 15